Indianapolis-based pharmaceutical company Eli Lilly announced Monday that it will sell a generic version of Humalog, its branded insulin product. The generic will cost $137 per vial, or half as much as Humalog. Lilly’s move is seen as a partial concession to lawmakers who have grilled pharma companies about the high cost of life-saving prescription drugs. But the company will keep Humalog at its current price. Why this two-tiered drug strategy?
Click the audio player above to hear the full story.
Marketplace is on a mission.
We believe Main Street matters as much as Wall Street, economic news is made relevant and real through human stories, and a touch of humor helps enliven topics you might typically find…well, dull.
Through the signature style that only Marketplace can deliver, we’re on a mission to raise the economic intelligence of the country—but we don’t do it alone. We count on listeners and readers like you to keep this public service free and accessible to all. Will you become a partner in our mission today?